Beijing News (Reporter Kala Wang) Insight Investment and Financing Database shows that there were 12 investment and financing events in the global pharmaceuticals field last week, of which 42% were from Chinese companies, including AusperBio and Huaota. The highly anticipated fields include gene therapy, nucleic acid therapy, and targeted protein degradation therapy.
AusperBio Completes $73 Million Series B Financing, Which Will Mainly Be Used to Advance the Clinical Trials in China and Internationally for AHB-137 and Prepare for Early Commercialization. AusperBio is Committed to Developing Targeted Delivery of Small Nucleic Acid Drugs, with a Particular Focus on Functional Cure for Chronic Hepatitis B and Efficient Targeted Therapies for Liver Diseases. The Company’s Most Advanced Product is an Antisense Oligonucleotide Therapy, AHB-137, Designed to Achieve Functional Cure for Hepatitis B, Which Has Now Entered Phase II Clinical Trials.
Huaota, a subsidiary of Huahai Pharmaceutical, completes 200 million yuan financing exclusively invested by Haizhao Venture Capital. Huaota focuses on the research and development of novel biologics in areas such as oncology and autoimmune diseases, with 11 projects currently in clinical stages. Among them, the IL-36R monoclonal antibody for treating pustular psoriasis has entered a pivotal clinical stage; the anti-cancer drug PD-L1/VEGF bispecific antibody is in Phase II clinical trials.
Eli Radiopharma Completes Angel Round Financing of RMB 100 Million: Funding to Build Innovative Radioactive Drug Platform, Accelerate Clinical Projects and Expand Team Size
Proofread by Mu Xiangtong